Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 12/2018

26.06.2018 | Review

Primary Tumor Location in Colorectal Cancer: Comparison of Right- and Left-Sided Colorectal Cancer Characteristics for the Interventional Radiologist

verfasst von: Shamar Young, Jafar Golzarian

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

One area which has emerged as an important factor for predicting molecular profile and treatment outcomes in metastatic colorectal cancer (mCRC) is primary tumor location. The importance of molecular characteristics of colorectal cancer has been firmly established in terms of prognosis and treatment algorithms for many years. Recent studies have also suggested that molecular profiles are important in locoregional therapies as well, with some data suggesting changes in treatment algorithms based on tumor location. Therefore, it is important for interventional radiologists to understand the basic molecular characteristics and development pathways of mCRC. Here, these disease characteristics are reviewed and the differences in left- versus right-sided primary tumor location are explored.
Literatur
1.
Zurück zum Zitat Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicenter, randomized, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71.CrossRef Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicenter, randomized, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71.CrossRef
2.
Zurück zum Zitat Sharma RA, Wasan HS, Van Hazel GA, et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. J Clin Oncol. 2017;35(15 suppl):3507.CrossRef Sharma RA, Wasan HS, Van Hazel GA, et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. J Clin Oncol. 2017;35(15 suppl):3507.CrossRef
4.
Zurück zum Zitat Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57–64.CrossRef Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57–64.CrossRef
5.
Zurück zum Zitat Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001.CrossRef Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001.CrossRef
6.
Zurück zum Zitat Seligmann J, Elliott F, Richman S, et al. Primary tumour location (PTL) as a prognostic and predictive factor in advanced colorectal cancer: data from 2075 patients in randomized trials. Ann Oncol. 2014;25(suppl4): iv167–iv209. Seligmann J, Elliott F, Richman S, et al. Primary tumour location (PTL) as a prognostic and predictive factor in advanced colorectal cancer: data from 2075 patients in randomized trials. Ann Oncol. 2014;25(suppl4): iv167–iv209.
7.
Zurück zum Zitat Zhang Y, Ma J, Zhang S, et al. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis. 2015;30(9):1173–83.CrossRef Zhang Y, Ma J, Zhang S, et al. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis. 2015;30(9):1173–83.CrossRef
8.
Zurück zum Zitat Shady W, Petre EN, Vakiani, et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget. 2017;8(39):66117–27.CrossRef Shady W, Petre EN, Vakiani, et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget. 2017;8(39):66117–27.CrossRef
9.
Zurück zum Zitat Ziv E, Bergen M, Yarmohammadi H, et al. PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget. 2017;8(14):23529–38.CrossRef Ziv E, Bergen M, Yarmohammadi H, et al. PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget. 2017;8(14):23529–38.CrossRef
10.
Zurück zum Zitat Wright M, Beaty JS, Ternent CA. Molecular markers for colorectal cancer. Surg Clin North Am. 2017;97(3):683–701.CrossRef Wright M, Beaty JS, Ternent CA. Molecular markers for colorectal cancer. Surg Clin North Am. 2017;97(3):683–701.CrossRef
11.
Zurück zum Zitat Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.CrossRef Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.CrossRef
12.
Zurück zum Zitat Grady WM, Carthers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–99.CrossRef Grady WM, Carthers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–99.CrossRef
13.
Zurück zum Zitat Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. J Mol Sci. 2017;18(1):piiE197.CrossRef Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. J Mol Sci. 2017;18(1):piiE197.CrossRef
14.
Zurück zum Zitat Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008;29:673–80.CrossRef Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008;29:673–80.CrossRef
15.
Zurück zum Zitat Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015;149:1177–90.CrossRef Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015;149:1177–90.CrossRef
16.
Zurück zum Zitat Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer. 2003;2:41.CrossRef Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer. 2003;2:41.CrossRef
17.
Zurück zum Zitat Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci. 2017;18(4):pii:E752.CrossRef Miyamoto Y, Suyama K, Baba H. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. Int J Mol Sci. 2017;18(4):pii:E752.CrossRef
18.
Zurück zum Zitat Sorich MJ, Wiese MD, Rowland A, Kicheneadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in meta-analysis of randomized, controlled trials. Ann Onol. 2015;26(1):13–21.CrossRef Sorich MJ, Wiese MD, Rowland A, Kicheneadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in meta-analysis of randomized, controlled trials. Ann Onol. 2015;26(1):13–21.CrossRef
19.
Zurück zum Zitat Bahnassy AA, Zekri AR, Salem SE, et al. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: prognostic and predictive values. Histol Histopathol. 2014;29:207–16.PubMed Bahnassy AA, Zekri AR, Salem SE, et al. Differential expression of p53 family proteins in colorectal adenomas and carcinomas: prognostic and predictive values. Histol Histopathol. 2014;29:207–16.PubMed
20.
Zurück zum Zitat Tran NH, Cavalcante LL, Lubner SJ, et al. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015;7(5):252–62.CrossRef Tran NH, Cavalcante LL, Lubner SJ, et al. Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol. 2015;7(5):252–62.CrossRef
21.
Zurück zum Zitat Rosty C, Young JP, Walsh MD, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS ONE. 2013;8(6):e65479.CrossRef Rosty C, Young JP, Walsh MD, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS ONE. 2013;8(6):e65479.CrossRef
22.
Zurück zum Zitat Nowak JA, Hornick JL. Molecular evaluation of colorectal adenocarcinoma: current practice and emerging concepts. Surg Pathol Clinc. 2016;9:427–39.CrossRef Nowak JA, Hornick JL. Molecular evaluation of colorectal adenocarcinoma: current practice and emerging concepts. Surg Pathol Clinc. 2016;9:427–39.CrossRef
23.
Zurück zum Zitat Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol. 2014;42(1):124–39.CrossRef Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol. 2014;42(1):124–39.CrossRef
24.
Zurück zum Zitat Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med. 2011;135(10):1269–77.CrossRef Geiersbach KB, Samowitz WS. Microsatellite instability and colorectal cancer. Arch Pathol Lab Med. 2011;135(10):1269–77.CrossRef
25.
Zurück zum Zitat Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90–6.CrossRef Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90–6.CrossRef
26.
Zurück zum Zitat Farina-Sarasqueta A, van Linjnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396–402.CrossRef Farina-Sarasqueta A, van Linjnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010;21(12):2396–402.CrossRef
27.
Zurück zum Zitat Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.CrossRef Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.CrossRef
28.
Zurück zum Zitat Ribic CM, Sargant DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.CrossRef Ribic CM, Sargant DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.CrossRef
29.
Zurück zum Zitat Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96(15):8681–6.CrossRef Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96(15):8681–6.CrossRef
30.
Zurück zum Zitat Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics. 2016;8:25.CrossRef Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clin Epigenetics. 2016;8:25.CrossRef
31.
Zurück zum Zitat Jover R, Nguyen TP, Perez-Carbonell L, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 2011;140(4):1174–81.CrossRef Jover R, Nguyen TP, Perez-Carbonell L, et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology. 2011;140(4):1174–81.CrossRef
32.
Zurück zum Zitat Kim YS, Deng G. Epignenetic changes (aberrant DNA methylation) in colorectal neoplasia. Gut Liver. 2007;1(1):1–11.CrossRef Kim YS, Deng G. Epignenetic changes (aberrant DNA methylation) in colorectal neoplasia. Gut Liver. 2007;1(1):1–11.CrossRef
33.
Zurück zum Zitat Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–54.CrossRef Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–54.CrossRef
34.
Zurück zum Zitat Nagasaka T, Koi M, Kloor M, et al. Mutations in both KRAS and BRAF may contribute to methylator phenotype in colon cancer. Gastroenterology. 2008;134(7):1950–60.CrossRef Nagasaka T, Koi M, Kloor M, et al. Mutations in both KRAS and BRAF may contribute to methylator phenotype in colon cancer. Gastroenterology. 2008;134(7):1950–60.CrossRef
35.
Zurück zum Zitat Puccinin A, Berger MD, Naseem M, et al. Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta. 2017;1868(2):439–48. Puccinin A, Berger MD, Naseem M, et al. Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta. 2017;1868(2):439–48.
36.
Zurück zum Zitat Juo YY, Johnstom FM, Zhang DY, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014;25:2314–27.CrossRef Juo YY, Johnstom FM, Zhang DY, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014;25:2314–27.CrossRef
37.
Zurück zum Zitat Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–93.CrossRef Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–93.CrossRef
38.
Zurück zum Zitat LaPointe LC, Dunne R, Brown GS, et al. Map of differential transcript expression in the normal human large intesting. Physiol Genomics. 2008;33(1):50–64.CrossRef LaPointe LC, Dunne R, Brown GS, et al. Map of differential transcript expression in the normal human large intesting. Physiol Genomics. 2008;33(1):50–64.CrossRef
39.
Zurück zum Zitat Lacopeta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101(5):403–8.CrossRef Lacopeta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101(5):403–8.CrossRef
40.
Zurück zum Zitat Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98.CrossRef Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98.CrossRef
41.
Zurück zum Zitat Saidi HS, Karuri D, Nyaim EO. Correlation of clinical data, anatomical site and disease stage in colorectal cancer. East Afr Med J. 2008;85(6):259–62.CrossRef Saidi HS, Karuri D, Nyaim EO. Correlation of clinical data, anatomical site and disease stage in colorectal cancer. East Afr Med J. 2008;85(6):259–62.CrossRef
42.
Zurück zum Zitat Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623–32.CrossRef Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623–32.CrossRef
43.
Zurück zum Zitat Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261–70.CrossRef Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261–70.CrossRef
44.
Zurück zum Zitat Breivik J, Lothe RA, Meling GI, Rognum TO, Borresen-Dale AL, Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer. 1997;74(6):664–9.CrossRef Breivik J, Lothe RA, Meling GI, Rognum TO, Borresen-Dale AL, Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer. 1997;74(6):664–9.CrossRef
45.
Zurück zum Zitat Mouradov D, Domingo E, Gibbs P, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013;108(11):1785–93.CrossRef Mouradov D, Domingo E, Gibbs P, et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013;108(11):1785–93.CrossRef
46.
Zurück zum Zitat Lan YT, Jen-Kou L, Lin CH, et al. Mutations in the RAS and PI3 K pathways are associated with metastatic location in colorectal cancers. J Surg Oncol. 2015;111(7):905–10.CrossRef Lan YT, Jen-Kou L, Lin CH, et al. Mutations in the RAS and PI3 K pathways are associated with metastatic location in colorectal cancers. J Surg Oncol. 2015;111(7):905–10.CrossRef
47.
Zurück zum Zitat Wang MJ, Ping J, Li Y, et al. Prognostic significance and molecular features of colorectal mucinous adenocarcinomas: a strobe-compliant study. Medicine (Baltimore). 2015;94(51):e2350.CrossRef Wang MJ, Ping J, Li Y, et al. Prognostic significance and molecular features of colorectal mucinous adenocarcinomas: a strobe-compliant study. Medicine (Baltimore). 2015;94(51):e2350.CrossRef
48.
Zurück zum Zitat Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA. 2014;111(51):18321–6.CrossRef Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA. 2014;111(51):18321–6.CrossRef
49.
Zurück zum Zitat Lowichik A, Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract. Mod Pathol. 1996;9(2):110–4.PubMed Lowichik A, Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract. Mod Pathol. 1996;9(2):110–4.PubMed
50.
Zurück zum Zitat Kirby JA, Bone M, Robertson H, Hudson M, Jones DE. The number of intraepithelial T cells decreases from ascending colon to rectum. J Clin Pathol. 2003;56(2):158.CrossRef Kirby JA, Bone M, Robertson H, Hudson M, Jones DE. The number of intraepithelial T cells decreases from ascending colon to rectum. J Clin Pathol. 2003;56(2):158.CrossRef
51.
Zurück zum Zitat Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.CrossRef Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.CrossRef
52.
Zurück zum Zitat Brule SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51(11):1405–14.CrossRef Brule SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51(11):1405–14.CrossRef
53.
Zurück zum Zitat Moretto R, Cremolini C, Rossini D, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist. 2016;21(8):9880994.CrossRef Moretto R, Cremolini C, Rossini D, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist. 2016;21(8):9880994.CrossRef
54.
Zurück zum Zitat Boisen MK, Joahnsen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(10):2554–9.CrossRef Boisen MK, Joahnsen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(10):2554–9.CrossRef
55.
Zurück zum Zitat Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3):piidju427.CrossRef Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3):piidju427.CrossRef
56.
Zurück zum Zitat Wong HL, Lee B, Field K, et al. Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer. 2016;15(2):e9–15.CrossRef Wong HL, Lee B, Field K, et al. Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer. 2016;15(2):e9–15.CrossRef
57.
Zurück zum Zitat Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609–18.CrossRef Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609–18.CrossRef
Metadaten
Titel
Primary Tumor Location in Colorectal Cancer: Comparison of Right- and Left-Sided Colorectal Cancer Characteristics for the Interventional Radiologist
verfasst von
Shamar Young
Jafar Golzarian
Publikationsdatum
26.06.2018
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 12/2018
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-018-2014-0

Weitere Artikel der Ausgabe 12/2018

CardioVascular and Interventional Radiology 12/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.